1-氧代-2,6-二氮杂螺[4.5]癸烷-6-羧酸叔丁酯 | 1221818-08-1

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 氮杂螺癸烷衍生物
• 中文名称: 1-氧代-2,6-二氮杂螺[4.5]癸烷-6-羧酸叔丁酯
• 英文名称: Tert-butyl 1-oxo-2,6-diazaspiro[4.5]decane-6-carboxylate
• CAS: 1221818-08-1
• 化学式: C₁₃H₂₂N₂O₃
• 分子量: 254.33
• InChiKey: DFRNFZFTUWABTE-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.3
• 重原子数：
  18
• 可旋转键数：
  2
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.85
• 拓扑面积：
  58.6
• 氢给体数：
  1
• 氢受体数：
  3

反应信息

• 作为反应物：
  描述：

  2-甲基-5-溴苯甲酸甲酯 、 1-氧代-2,6-二氮杂螺[4.5]癸烷-6-羧酸叔丁酯 在 copper(l) iodide 、 N,N-二甲基甘氨酸 、 potassium carbonate 、 sodium hydroxide 作用下， 以 甲醇 、 水 、 N,N-二甲基甲酰胺 为溶剂， 反应 31.0h， 生成 5-(6-(tert-butoxycarbonyl)-1-oxo-2,6-diazaspiro[4.5]decan-2-yl)-2-methylbenzoic acid
  参考文献：
  名称：

  WO2024121779A1

  摘要：

  公开号：

文献信息

• [EN] SPIRO-LACTAM NMDA RECEPTOR MODULATORS AND USES THEREOF<br/>[FR] MODULATEURS SPIRO-LACTAMES DES RÉCEPTEURS NMDA ET LEURS UTILISATIONS
  申请人：APTINYX INC

  公开号：WO2018026779A1

  公开（公告）日：2018-02-08

  Disclosed are compounds having potency in the modulation of NMDA receptor activity. Such compounds can be used in the treatment of conditions such as depression and related disorders. Orally delivered formulations and other pharmaceutically acceptable delivery forms of the compounds, including intravenous formulations, are also disclosed.

  揭示了具有调节NMDA受体活性潜力的化合物。这些化合物可用于治疗抑郁症和相关疾病。还披露了口服制剂和其他药学上可接受的化合物给药形式，包括静脉注射制剂。
• Inhibitors of cysteine proteases and methods of use thereof
  申请人：Pardes Biosciences, Inc.

  公开号：US11174231B1

  公开（公告）日：2021-11-16

  The disclosure provides compounds with warheads and their use in treating medical diseases or disorders, such as viral infections. Pharmaceutical compositions and methods of making various compounds with warheads are provided. The compounds are contemplated to inhibit proteases, such as the 3C, CL- or 3CL-like protease.

  本公开提供了带有弹头的化合物及其在治疗医学疾病或失调（如病毒感染）中的用途。提供了药物组合物和制造各种带弹头化合物的方法。这些化合物可用于抑制蛋白酶，如 3C、CL 或 3CL 样蛋白酶。
• Spiro-lactam NMDA receptor modulators and uses thereof
  申请人：Aptinyx Inc.

  公开号：US11299495B2

  公开（公告）日：2022-04-12

  Disclosed are compounds having potency in the modulation of NMDA receptor activity. Such compounds can be used in the treatment of conditions such as depression and related disorders. Orally delivered formulations and other pharmaceutically acceptable delivery forms of the compounds, including intravenous formulations, are also disclosed.

  所公开的化合物具有调节 NMDA 受体活性的功效。此类化合物可用于治疗抑郁症及相关疾病。此外，还公开了口服制剂和其他药学上可接受的化合物给药形式，包括静脉注射制剂。
• SPIRO-LACTAM NMDA RECEPTOR MODULATORS AND USES THEREOF
  申请人：Aptinyx Inc.

  公开号：US20220220119A1

  公开（公告）日：2022-07-14

  Disclosed are compounds having potency in the modulation of NMDA receptor activity. Such compounds can be used in the treatment of conditions such as depression and related disorders. Orally delivered formulations and other pharmaceutically acceptable delivery forms of the compounds, including intravenous formulations, are also disclosed.
• [EN] INHIBITORS OF CYSTEINE PROTEASES AND METHODS OF USE THEREOF<br/>[FR] INHIBITEURS DE CYSTÉINE PROTÉASES ET LEURS PROCÉDÉS D'UTILISATION
  申请人：PARDES BIOSCIENCES INC

  公开号：WO2021252644A1

  公开（公告）日：2021-12-16

  The disclosure provides compounds of formula II with warheads and their use in treating medical diseases or disorders, such as viral infections. Pharmaceutical compositions and methods of making various compounds with warheads are provided. The compounds are contemplated to inhibit proteases, such as the 3C, CL- or 3CL-like protease. Formula II